Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Approval for zuranolone might be in reach, but meeting sales expectations could be a different story.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.